Cancer Immunotherapy Peptides: Neoantigen Vaccines and Checkpoint Modulators

Overview

Cancer immunotherapy peptides harness the immune system to recognize and destroy tumor cells. Personalized neoantigen vaccines and checkpoint modulators represent cutting-edge approaches with significant clinical potential.

Key Concepts

Neoantigen Peptide Vaccines

Neoantigen Identification

• Tumor sequencing: Whole-exome and RNA sequencing
• HLA typing: Patient-specific MHC molecules
• Epitope prediction: NetMHCpan, IEDB algorithms
• Prioritization: Expression level, clonality, immunogenicity

Vaccine Design Principles

• Polyepitope vaccines: Multiple neoantigens per construct
• Long peptides (20-30 aa): Enhanced MHC class II presentation
• Modified peptides: Anchor residue optimization for binding
• Combination strategies: Neoantigen + adjuvant + immune modulator

Clinical Evidence

• Melanoma: >50% response rates in early trials
• Glioblastoma: Prolonged survival with personalized vaccines
• Pancreatic cancer: Combination with checkpoint inhibitors
• Colorectal cancer: MSI-high tumors responding best

Checkpoint Inhibitor Peptidomimetics

PD-1/PD-L1 Axis

• Peptide antagonists: Blocking PD-1/PD-L1 interaction
• Macrocyclic peptides: Enhanced stability and binding
• Oral bioavailability: Cell-permeable designs
• Combination potential: With other checkpoint inhibitors

CTLA-4 Modulators

• Peptide-based CTLA-4 blockade: Alternative to antibodies
• Dual checkpoint targeting: Single peptide hitting multiple targets
• Reduced immunogenicity: Humanized peptide sequences

Novel Checkpoint Targets

• LAG-3: T-cell exhaustion marker
• TIGIT: NK and T-cell inhibition
• TIM-3: Immune cell dysfunction
• VISTA: Myeloid cell suppression

Tumor-Targeting Peptides

Homing Peptides

• RGD peptides: Targeting integrin-expressing tumors
• NGR peptides: Aminopeptidase N targeting
• iRGD: Tumor-penetrating peptide
• CREKA: Fibrin-targeting in tumor vasculature

Peptide-Drug Conjugates (PDCs)

• Targeting moiety: Tumor-homing peptide
• Payload: Cytotoxic drug (maytansinoids, auristatins)
• Linker: Cleavable or non-cleavable
• Bystander effect: Killing neighboring cells

CAR-T Cell Peptide Enhancement

Peptide-MHC Guidance

• Peptide-MHC complexes: Directing T cells to tumor antigens
• Synthetic notch receptors: Peptide-activated signaling
• Dual-targeting: Combining peptide recognition with CAR

Peptide-Based Safety Switches

• Inducible caspase-9: Activated by small molecule peptide
• HSV-TK: Ganciclovir-mediated ablation
• RQR8: Dual-target safety switch

Clinical Applications

Current Approaches

• Sipuleucel-T: First FDA-approved cancer vaccine (prostate)
• Personalized neoantigen vaccines: Phase II trials in melanoma
• Checkpoint combinations: Peptide vaccines + anti-PD-1
• Adoptive T-cell therapy: Peptide-expanded tumor-infiltrating lymphocytes

Combination Strategies

• Peptide vaccine + checkpoint inhibitor: Synergistic T-cell activation
• Peptide + radiation: Immunogenic cell death enhancement
• Peptide + chemotherapy: Immune modulation
• Peptide + targeted therapy: Overcoming resistance

Manufacturing Challenges

Personalized Production

• Rapid manufacturing: <4 weeks from biopsy to vaccine
• Quality control: Ensuring peptide purity and identity
• Scale-up: Individual patient production
• Cost: Currently >$100,000 per patient

Off-the-Shelf Approaches

• Shared tumor antigens: WT1, survivin, MUC1
• Viral vectors: Encoding multiple peptides
• RNA vaccines: Encoding neoantigens
• Bacterial vectors: Immune stimulation

References

• Ott, P.A., et al. (2024). “Personal neoantigen vaccines for cancer immunotherapy.” Nature Medicine, 30(4), 1023-1035.
• Sahin, U., et al. (2023). “An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.” Nature, 585, 107-112.